Ketamine Therapy for Addiction

Ketamine for addiction is one of the most counterintuitive corners of psychedelic medicine — and one of the most carefully framed. Active substance use disorder is normally a contraindication for ketamine therapy. That is not a paradox or a marketing inconvenience — it is the clinical reality. The published evidence base (Krupitsky's 1990s–2000s alcohol-dependence and heroin-dependence trials, the Dakwar group's 2019 cocaine and 2020 alcohol RCTs at Columbia, and the 2022 KARE alcohol trial in the UK) was conducted in patients who had already detoxified and stabilized. Ketamine is not a detox tool. It does not replace medication-assisted treatment (buprenorphine or methadone for opioid use disorder; naltrexone or acamprosate for alcohol use disorder). And it is not a substitute for community recovery infrastructure (AA, SMART Recovery, peer support). Where ketamine appears to help is as an adjunct for patients who have already committed to recovery and struggle with depression or cravings as obstacles to long-term abstinence — particularly in comorbid TRD + AUD profiles. This article walks through that honestly.

Key takeaways

• Ketamine is off-label for any substance use disorder. Spravato is approved only for treatment-resistant depression and has no SUD indication.
• The strongest SUD ketamine evidence is for alcohol use disorder (Krupitsky 2002; Dakwar 2020; KARE 2022). Cocaine has moderate evidence (Dakwar 2014, 2017, 2019). Opioid use disorder has limited evidence.
• Active substance use is normally a contraindication. ATMA CENA typically requires a documented period of abstinence and stabilization before ketamine is considered.
• Ketamine is not a detox tool, not a replacement for buprenorphine/methadone (OUD) or naltrexone/acamprosate (AUD), and not a substitute for community recovery programs. It is best understood as an adjunct for committed-to-recovery patients with comorbid depression or persistent cravings.
• Ketamine itself has misuse potential, particularly in patients with SUD history. Screening and structured supervised dosing (no take-home) are part of safe practice.
• Psilocybin has stronger AUD-specific RCT evidence (Bogenschutz et al., JAMA Psychiatry 2022) but is accessible in Canada only via Health Canada's Special Access Program.

The paradox, stated honestly

Ketamine is being studied for addiction. It is also a controlled substance with misuse potential. People with active substance use disorders generally cannot safely access ketamine therapy. That tension is not a marketing problem; it is the clinical reality, and it shapes who is and is not a candidate.

Why active SUD is a contraindication:

1. Safety. Active use plus a reinforcing dissociative substance increases overdose, drug interaction, and cross-addiction risk.
2. Efficacy. The therapeutic value of ketamine in SUD trials appears tied to psychological consolidation work that requires sobriety to engage with.
3. Neurobiology. Active substance use disrupts the synaptic plasticity that ketamine's mechanism depends on.
4. Screening reality. The published RCTs all enrolled detoxified patients — Krupitsky's were detoxified in inpatient settings before randomization. Real-world clinics, including ATMA CENA, require documented abstinence, typically 30–90 days, before ketamine is considered.

What ketamine is good for in SUD:

• Adjunctive treatment for comorbid TRD + AUD where depression is a documented obstacle to recovery participation.
• A potential consolidation tool after detox and psychosocial stabilization, paired with relapse-prevention psychotherapy.
• Possibly useful for cravings in selected stimulant use disorder patients post-stabilization.

What ketamine is not good for:

• Acute withdrawal management (ketamine doesn't reduce withdrawal; it isn't a detox medication).
• Replacing buprenorphine, methadone, naltrexone, or acamprosate.
• Patients without an established recovery support system.
• Patients with active substance use.

What is ketamine-assisted therapy in this context?

Ketamine therapy uses sub-anaesthetic doses of ketamine — a Health Canada-approved anaesthetic — paired with structured psychotherapy. Health Canada has approved ketamine as an anaesthetic; psychiatric use is off-label. Spravato (intranasal esketamine) is Health Canada-approved only for treatment-resistant MDD; it has no SUD indication. All ketamine-for-addiction in Canada uses racemic ketamine off-label, in carefully screened recovery-stabilized patients.

For the full mechanism breakdown, see What Is Ketamine Therapy?.

What the evidence actually shows — by substance

Alcohol Use Disorder — strongest evidence

Krupitsky and Grinenko 1997 / Krupitsky 2002 — J Psychoactive Drugs and subsequent reports — Russian "Ketamine Psychedelic Therapy" (KPT) for alcohol dependence. Detoxified inpatients received psychedelic-dose IM ketamine (~2.0 mg/kg) integrated with existential psychotherapy. One-year abstinence rates of ~66% in the KPT group versus ~24% in conventional treatment (Krupitsky archive). Foundational but methodologically dated; high doses and clinical model differ from contemporary KAP.

Dakwar et al. 2020 — American Journal of Psychiatry — single ketamine infusion (0.71 mg/kg over 52 minutes) plus motivational enhancement therapy in adults with alcohol use disorder, midazolam-controlled. The ketamine arm showed significantly more days abstinent and longer time to relapse over the 21-day follow-up.

Grabski et al. 2022 — KARE trial — American Journal of Psychiatry — UK RCT of three weekly IV ketamine infusions (0.8 mg/kg) plus relapse-prevention–based psychological therapy in 96 detoxified patients with alcohol use disorder. The combined ketamine + therapy arm had significantly more days abstinent at 6-month follow-up versus placebo + alcohol education. The most rigorous RCT for ketamine in AUD to date.

The honest summary for AUD: ketamine, when paired with psychological therapy and given to detoxified and stabilized patients, increases abstinence durability. Effect sizes are meaningful; the protocol is not "ketamine alone."

Cocaine Use Disorder — moderate evidence

Dakwar et al. 2014 — American Journal of Psychiatry — first US RCT of single-dose ketamine in cocaine-dependent patients. Significant reduction in cocaine craving and use compared with active control.

Dakwar et al. 2019 — American Journal of Psychiatry — single ketamine infusion (0.5 mg/kg) combined with mindfulness-based behavioural modification in cocaine-dependent patients. End-of-treatment abstinence ~48.2% (ketamine) versus ~10.7% (midazolam control). One of the cleanest stimulant-use-disorder ketamine results published.

The honest summary for cocaine use disorder: meaningful proof-of-concept in detoxified, treatment-engaged patients; replication and longer-duration studies remain needed.

Opioid Use Disorder — limited evidence

Krupitsky 2007 — heroin-dependent detoxified patients receiving ketamine psychedelic therapy plus group counselling. RCTs at 1 month and 2 years showed increased abstinence in the higher-dose ketamine groups versus low-dose. Methodologically older; not replicated at scale in the modern era.

The honest summary for opioid use disorder: very limited evidence; standard care remains buprenorphine, methadone, or extended-release naltrexone with psychosocial support. Ketamine is not a credible first- or second-line OUD treatment in current Canadian guidelines.

Other substances

Cannabis use disorder, methamphetamine use disorder, and benzodiazepine use disorder have minimal published ketamine RCT evidence. ATMA CENA generally evaluates these case-by-case.

How psilocybin AUD evidence compares

Bogenschutz et al. 2022 — JAMA Psychiatry — randomized double-blind trial in 95 patients with alcohol use disorder. Two psilocybin sessions (25 mg/70 kg and 25 mg/70 kg or 30 mg/70 kg) plus 12 weeks of manualized psychotherapy versus diphenhydramine + same psychotherapy. Mean percentage of heavy drinking days over 32 weeks was 9.7% (psilocybin) versus 23.6% (placebo) — a robust between-group difference.

In Canada, psilocybin is Schedule III under the CDSA but accessible for medical use through Health Canada's Special Access Program (SAP). Approvals are case-specific, prescriber-initiated, and capacity-limited. Psilocybin for AUD is not yet a Health Canada-approved indication; SAP access has been more common for end-of-life distress and treatment-resistant depression.

The honest comparison: psilocybin has stronger AUD-specific RCT evidence than ketamine. Ketamine is more accessible because it is off-label legal rather than SAP-gated. The right answer depends on access pathway, urgency, and prescriber willingness to pursue an SAP application. This article does not promote psilocybin; it acknowledges the comparison because patients deserve honest framing.

For the broader cross-treatment view, see Ketamine vs Psilocybin Therapy.

How ATMA CENA screens addiction patients

The ATMA CENA intake call works through several specific screening points for SUD:

1. Diagnosis and current status. DSM-5 SUD diagnosis (substance, severity); current use vs documented abstinence; recent use timeline.
2. Abstinence period. ATMA CENA typically requires 30–90 days of documented abstinence with negative urine drug screening before ketamine is considered. Specific duration is individualized to substance, severity, and stability.
3. Established addiction care. Engagement with addiction medicine (buprenorphine/methadone for OUD; naltrexone, acamprosate for AUD), psychosocial support (AA, SMART Recovery, group therapy, individual addiction counsellor), and a primary recovery framework. Ketamine does not replace these.
4. Comorbid psychiatric diagnosis. TRD or PTSD comorbidity is the most common ATMA CENA-suitable profile. The depression/PTSD is the primary target indication; SUD-specific benefit may follow as a secondary effect.
5. Misuse risk assessment. History of ketamine misuse is a hard exclusion. Other dissociative-substance misuse history is a relative contraindication. Take-home ketamine is generally not used; supervised in-clinic dosing is the standard.
6. Structured care plan. Coordinated team (ATMA CENA + addiction physician + therapist + community recovery support); urine drug screening before each session.

For full eligibility detail, see How to Qualify for Ketamine Therapy in Canada.

Canadian addiction medicine context

Standard Canadian addiction treatment frameworks — relevant to patients evaluating ketamine — are:

• Opioid use disorder. Buprenorphine/naloxone (preferred) or methadone as first-line; psychosocial support; harm reduction. The Canadian Centre on Substance Use and Addiction (CCSA) and the BC Centre on Substance Use publish national guidelines.
• Alcohol use disorder. Naltrexone, acamprosate, and (in some cases) topiramate or gabapentin; psychosocial support including motivational enhancement, cognitive-behavioural therapy, and 12-step or SMART Recovery participation. CRISM publishes the Canadian guidelines.
• Stimulant use disorder. No FDA- or Health Canada-approved pharmacotherapy; psychosocial treatment with contingency management, cognitive-behavioural therapy, and community recovery is standard.

Ketamine sits outside these standard frameworks. CCSA does not currently endorse ketamine for SUD treatment. The clinically defensible role for ketamine in SUD is as an adjunct for comorbid TRD or trauma in patients otherwise stabilized on standard addiction care.

Cost and insurance

ATMA CENA's published KAT pricing applies: KAT Psychedelic Pathway from CAD $1,585 + $795 per additional session; KAT Psycholytic Pathway from CAD $1,530 + $740 per additional session; customized programs CAD $2,325–$6,930. A non-refundable deposit of CAD $300 applies. For full pricing context, see Ketamine Therapy Cost in Canada.

Insurance reality for SUD patients:

• Spravato — for comorbid TRD only (where depression is documented and meets TRD criteria), prior authorization is sometimes available.
• Generic IV/IM/SL ketamine — generally not covered by private insurance for psychiatric or SUD use.
• Provincial drug plans do not cover off-label ketamine for SUD.
• Workers' compensation and VAC — relevant where SUD is comorbid with compensable TRD or PTSD.

For full insurance navigation, see Insurance Coverage for Ketamine Therapy.

Frequently asked questions

Is ketamine approved for addiction in Canada? No. Ketamine is approved by Health Canada as an anaesthetic; addiction-related use is off-label. Spravato is approved only for treatment-resistant depression and has no SUD indication.

Why is active substance use disorder a contraindication? Safety (overdose, drug interactions, cross-addiction risk), efficacy (the therapeutic value depends on psychological work that requires sobriety), neurobiology (active use disrupts the synaptic plasticity ketamine engages), and screening reality (the published RCTs enrolled detoxified patients).

How long do I need to be abstinent before ketamine is considered? Typically 30–90 days of documented abstinence with negative urine drug screening, individualized to substance, severity, and stability. ATMA CENA's intake call works through this with you.

Can ketamine help me detox? No. Ketamine is not a detox medication. It does not reduce withdrawal symptoms from alcohol, opioids, benzodiazepines, or stimulants. Standard detox approaches (medically supervised withdrawal, often inpatient, with appropriate pharmacotherapy) remain the entry point.

Does ketamine replace buprenorphine or methadone for opioid use disorder? No. Buprenorphine/naloxone or methadone remain first-line OUD pharmacotherapy in Canadian guidelines. Ketamine is not a replacement. It might, in a stabilized patient with comorbid TRD, be considered as an adjunct for the depression component.

What's the strongest evidence for ketamine in addiction? Alcohol use disorder, particularly the Dakwar 2020 Am J Psychiatry infusion + motivational enhancement therapy RCT and the Grabski et al. 2022 KARE trial pairing three IV ketamine infusions with relapse-prevention psychological therapy. Cocaine use disorder has moderate evidence (Dakwar 2014, 2017, 2019). Opioid use disorder has limited evidence.

Has psilocybin been studied for AUD? Yes — Bogenschutz et al. 2022 in JAMA Psychiatry showed substantial reductions in heavy drinking days with two psilocybin sessions plus psychotherapy versus placebo + same psychotherapy. Stronger AUD-specific evidence than ketamine, but psilocybin in Canada is accessible only via Health Canada's Special Access Program.

Is ketamine itself addictive? Ketamine has misuse potential, particularly via recreational unsupervised use. In supervised in-clinic protocols at sub-anaesthetic doses, dependence has not emerged as a clinical issue in published trials. History of ketamine misuse is a hard exclusion at ATMA CENA; take-home ketamine is generally not used.

What about Matthew Perry? The Matthew Perry incident involved unsupervised, non-clinical ketamine use far outside any therapeutic protocol — and is exactly why supervised in-clinic dosing, structured screening, and absence of take-home dispensing are the standard of care in legitimate KAP programs. Patients deserve to be aware of misuse risk; legitimate clinical protocols are designed around it.

Can I do ketamine therapy without my addiction physician knowing? No. Coordinated care is required. ATMA CENA's intake will request release-of-information consent to communicate with your addiction physician and primary care provider. Going around your addiction team is unsafe and incompatible with this model of care.

What's the most realistic path to ketamine therapy if I'm in recovery? The clearest path is comorbid TRD or PTSD with stable AUD or stimulant use disorder recovery, on appropriate addiction medication, engaged in psychosocial recovery infrastructure, with documented 30–90+ days abstinence. Ketamine then becomes an adjunct for the depression or trauma component, in a coordinated multidisciplinary care plan.

Where can I get ketamine therapy in Canada? See the city- and province-specific articles in this cluster: Calgary, Edmonton, Winnipeg, Toronto/GTA, Montreal, Ottawa, Halifax, Vancouver, Victoria BC, Kelowna, Saskatoon, Mississauga, Hamilton, London ON.

Sources

1. ATMA CENA — coordinated care: https://psychedelic.healthcare/find-care
2. Krupitsky EM, Grinenko AY (1997 / 2002). Ketamine psychedelic therapy (KPT) for alcohol dependence and heroin addiction. https://pubmed.ncbi.nlm.nih.gov/12495789/
3. Dakwar E, et al. (2014). The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry. https://pubmed.ncbi.nlm.nih.gov/23845443/
4. Dakwar E, et al. (2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/31230464/
5. Dakwar E, et al. (2020). A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.2019.18101123
6. Grabski M, et al. (2022). Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder (KARE). Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/34855456/
7. Jones JL, et al. (2018). Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2018.00277/full
8. Worrell SD, Gould TJ (2021) and Ezquerra-Romano II, et al. (2018). Reviews on ketamine mechanisms in addiction. Neuropharmacology.
9. Bogenschutz MP, et al. (2022). Psilocybin-assisted treatment for alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625
10. NCBI Bookshelf — Ketamine for Adults With Substance Use Disorders: https://www.ncbi.nlm.nih.gov/books/NBK602506/
11. Health Canada — Ketamine and Controlled Drugs and Substances Act: https://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/ketamine.html
12. Health Canada — Special Access Program (psychedelic-assisted psychotherapy): https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
13. CCSA / CRISM — Canadian Substance Use Best Practices: https://crism.ca/

Related articles in this cluster

• Ketamine Therapy in Canada
• What Is Ketamine Therapy?
• Ketamine Therapy for Depression
• Ketamine Therapy for Treatment-Resistant Depression (deep dive)
• Ketamine Therapy for PTSD
• Ketamine Therapy for Anxiety
• Ketamine vs Psilocybin Therapy
• How to Qualify for Ketamine Therapy in Canada
• Insurance Coverage for Ketamine Therapy
• Find care near you

Last updated: 2026-05-06